Aditxt's Adivir, Inc., Agreed To Acquire All Outstanding Class A Common Shares Of Appili Under The Third Amending Agreement; Transaction Is Conditional Upon Aditxt Raising At Least $20M In Financing Before Closing
Appili Therapeutics Reports Q1 Results
Aditxt Signs Second Amendment to Arrangement Agreement With Appili Therapeutics
Appili Therapeutics Announces Second Amendment to Arrangement Agreement
Appili Therapeutics Announces Amendment to Arrangement Agreement and Increase to Bridge Loan
Appili Therapeutics Announces Additional Bridge Loan From Bloom Burton & Co.
Aditxt Signs Agreement to Acquire Appili Therapeutics
Appili Therapeutics Reports Q3 Results
Appili Therapeutics Says Patent Issued For Biodefence Vaccine Candidate ATI-1701, Provides Update on Bridge Loan
Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ (ATI-1501) Metronidazole Oral Suspension
Appili Therapeutics GAAP EPS of -C$0.01
Press Release: Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024
Appili Therapeutics – Press Release Correction
Appili Therapeutics Net Loss of $0.08 Per Share For FY 2023
Appili Therapeutics GAAP EPS of -C$0.08
Appili Therapeutics Announces Issuance of Patent for ATI-1501 Liquid Oral Reformulation of Metronidazole
Appili Therapeutics Secures Contract for ATI-1701 Funding From U.S. Air Force Academy
Appili Therapeutics Appoints Dr. Gary Nabors as Chief Development Officer
Appili Therapeutics Inc. Expected to Post FY2023 Earnings of ($0.08) Per Share (TSE:APL)
Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to Support the ATI-1701 Biodefense Vaccine Program
No Data
No Data